- Home
- VIRX vs DOMH Comparison
VIRX vs DOMH Comparison
Compare VIRX & DOMH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIRX
- DOMH
- Stock Information
- Founded
- VIRX 2007
- DOMH 1967
- Country
- VIRX United States
- DOMH United States
- Employees
- VIRX N/A
- DOMH N/A
- Industry
- VIRX Biotechnology: Pharmaceutical Preparations
- DOMH Biotechnology: Pharmaceutical Preparations
- Sector
- VIRX Health Care
- DOMH Health Care
- Exchange
- VIRX Nasdaq
- DOMH Nasdaq
- Market Cap
- VIRX 7.0M
- DOMH 7.3M
- IPO Year
- VIRX N/A
- DOMH N/A
- Fundamental
- Price
- VIRX $0.19
- DOMH $1.18
- Analyst Decision
- VIRX Buy
- DOMH
- Analyst Count
- VIRX 4
- DOMH 0
- Target Price
- VIRX $5.00
- DOMH N/A
- AVG Volume (30 Days)
- VIRX 2.3M
- DOMH 61.3K
- Earning Date
- VIRX 11-13-2024
- DOMH 11-08-2024
- Dividend Yield
- VIRX N/A
- DOMH N/A
- EPS Growth
- VIRX N/A
- DOMH N/A
- EPS
- VIRX N/A
- DOMH N/A
- Revenue
- VIRX N/A
- DOMH $12,589,000.00
- Revenue This Year
- VIRX N/A
- DOMH N/A
- Revenue Next Year
- VIRX N/A
- DOMH N/A
- P/E Ratio
- VIRX N/A
- DOMH N/A
- Revenue Growth
- VIRX N/A
- DOMH 1117.50
- 52 Week Low
- VIRX $0.13
- DOMH $0.83
- 52 Week High
- VIRX $1.31
- DOMH $3.20
- Technical
- Relative Strength Index (RSI)
- VIRX 48.39
- DOMH 40.48
- Support Level
- VIRX $0.20
- DOMH $0.83
- Resistance Level
- VIRX $0.24
- DOMH $1.29
- Average True Range (ATR)
- VIRX 0.03
- DOMH 0.16
- MACD
- VIRX -0.00
- DOMH 0.00
- Stochastic Oscillator
- VIRX 34.27
- DOMH 51.94
About VIRX Viracta Therapeutics Inc.
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company's oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.